These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12943231)

  • 21. Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins.
    Salvatore D; Barone MV; Salvatore G; Melillo RM; Chiappetta G; Mineo A; Fenzi G; Vecchio G; Fusco A; Santoro M
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3898-907. PubMed ID: 11061555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
    Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
    Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.
    Mechler C; Bounacer A; Suarez H; Saint Frison M; Magois C; Aillet G; Gaulier A
    Br J Cancer; 2001 Dec; 85(12):1831-7. PubMed ID: 11747322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas.
    Puxeddu E; Moretti S; Giannico A; Martinelli M; Marino C; Avenia N; Cristofani R; Farabi R; Reboldi G; Ribacchi R; Pontecorvi A; Santeusanio F
    Eur J Endocrinol; 2003 May; 148(5):505-13. PubMed ID: 12720532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.
    Carlomagno F; Vitagliano D; Guida T; Ciardiello F; Tortora G; Vecchio G; Ryan AJ; Fontanini G; Fusco A; Santoro M
    Cancer Res; 2002 Dec; 62(24):7284-90. PubMed ID: 12499271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas.
    Jhiang SM; Sagartz JE; Tong Q; Parker-Thornburg J; Capen CC; Cho JY; Xing S; Ledent C
    Endocrinology; 1996 Jan; 137(1):375-8. PubMed ID: 8536638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice.
    Santoro M; Chiappetta G; Cerrato A; Salvatore D; Zhang L; Manzo G; Picone A; Portella G; Santelli G; Vecchio G; Fusco A
    Oncogene; 1996 Apr; 12(8):1821-6. PubMed ID: 8622903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential responses of human papillary thyroid cancer cell lines carrying the RET/PTC1 rearrangement or a BRAF mutation to MEK1/2 inhibitors.
    Henderson YC; Fredrick MJ; Clayman GL
    Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):810-5. PubMed ID: 17709622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of Ret/PTC1, -2, -3, -delta3 and -4 in German papillary thyroid carcinoma.
    Mayr B; Pötter E; Goretzki P; Rüschoff J; Dietmaier W; Hoang-Vu C; Dralle H; Brabant G
    Br J Cancer; 1998 Mar; 77(6):903-6. PubMed ID: 9528832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Orthovanadate-induced cell death in RET/PTC1-harboring cancer cells involves the activation of caspases and altered signaling through PI3K/Akt/mTOR.
    Gonçalves AP; Videira A; Soares P; Máximo V
    Life Sci; 2011 Sep; 89(11-12):371-7. PubMed ID: 21807000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early cellular abnormalities induced by RET/PTC1 oncogene in thyroid-targeted transgenic mice.
    Cho JY; Sagartz JE; Capen CC; Mazzaferri EL; Jhiang SM
    Oncogene; 1999 Jun; 18(24):3659-65. PubMed ID: 10380889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase.
    De Falco V; Castellone MD; De Vita G; Cirafici AM; Hershman JM; Guerrero C; Fusco A; Melillo RM; Santoro M
    Cancer Res; 2007 Jan; 67(1):381-90. PubMed ID: 17210721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC.
    Kim YR; Byun HS; Won M; Park KA; Kim JM; Choi BL; Lee H; Hong JH; Park J; Seok JH; Kim DW; Shong M; Park SK; Hur GM
    BMC Cancer; 2008 May; 8():144. PubMed ID: 18498667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation.
    Cassinelli G; Favini E; Degl'Innocenti D; Salvi A; De Petro G; Pierotti MA; Zunino F; Borrello MG; Lanzi C
    Neoplasia; 2009 Jan; 11(1):10-21. PubMed ID: 19107227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.
    Fenton MS; Marion KM; Salem AK; Hogen R; Naeim F; Hershman JM
    Thyroid; 2010 Sep; 20(9):965-74. PubMed ID: 20629553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of silencing the RET/PTC1 oncogene in papillary thyroid carcinoma by siRNA-squalene nanoparticles with and without fusogenic companion GALA-cholesterol.
    Ali HM; Maksimenko A; Urbinati G; Chapuis H; Raouane M; Desmaële D; Yasuhiro H; Harashima H; Couvreur P; Massaad-Massade L
    Thyroid; 2014 Feb; 24(2):327-38. PubMed ID: 23885719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RET activation in adult and childhood papillary thyroid carcinoma using a reverse transcriptase-n-polymerase chain reaction approach on archival-nested material.
    Williams GH; Rooney S; Thomas GA; Cummins G; Williams ED
    Br J Cancer; 1996 Aug; 74(4):585-9. PubMed ID: 8761374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.
    Lodyga M; De Falco V; Bai XH; Kapus A; Melillo RM; Santoro M; Liu M
    Oncogene; 2009 Feb; 28(7):937-49. PubMed ID: 19060924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Effect of papillary thyroid carcinoma related gene PTC1 on subcellular localization and function of ATM cell].
    Tie Y; Mao JP; Liu B; Song Y; Dong Y; Sun ZX
    Ai Zheng; 2004 May; 23(5):487-92. PubMed ID: 15142440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. H4(D10S170), a gene frequently rearranged with RET in papillary thyroid carcinomas: functional characterization.
    Celetti A; Cerrato A; Merolla F; Vitagliano D; Vecchio G; Grieco M
    Oncogene; 2004 Jan; 23(1):109-21. PubMed ID: 14712216
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.